H.R. 10369 · 119th Congress

Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026

Stage
In committee
Sponsor
Ryan Mackenzie
Introduced
2026-09-14
Latest action
2026-09-14 · Introduced in House

Action history

  1. 2026-09-14Introduced in House
  2. 2026-09-14Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  3. 2026-09-14Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  4. 2026-09-14Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.